Medical management of pulmonary disease caused by Mycobacterium avium complex

The current medical therapy for Mycobacterium avium complex is controversial. American Thoracic Society recommendations advocate empiric therapy with drug susceptibility testing only for clarithromycin. At National Jewish, where we mainly see cases complicated by treatment failure and drug intoleran...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinics in chest medicine Jg. 23; H. 3; S. 633
1. Verfasser:	Iseman, Michael D
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.09.2002
Schlagworte:	Anti-Bacterial Agents Antitubercular Agents - therapeutic use Clinical Trials as Topic Drug Therapy, Combination - therapeutic use Humans Microbial Sensitivity Tests Mycobacterium avium Complex - pathogenicity Mycobacterium avium-intracellulare Infection - drug therapy Mycobacterium avium-intracellulare Infection - microbiology Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology
ISSN:	0272-5231
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The current medical therapy for Mycobacterium avium complex is controversial. American Thoracic Society recommendations advocate empiric therapy with drug susceptibility testing only for clarithromycin. At National Jewish, where we mainly see cases complicated by treatment failure and drug intolerance, we use in vitro susceptibility testing and therapeutic drug monitoring to optimize efficacy and reduce toxicity.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0272-5231
DOI:	10.1016/s0272-5231(02)00023-0